Sino Biopharmaceutica Financials
| SBHMY Stock | USD 9.05 0.00 0.00% |
Sino |
Please note, the imprecision that can be found in Sino Biopharmaceutica's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sino Biopharmaceutical Ltd. Check Sino Biopharmaceutica's Beneish M Score to see the likelihood of Sino Biopharmaceutica's management manipulating its earnings.
Sino Biopharmaceutica Stock Summary
Sino Biopharmaceutica competes with Adagene. Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the Peoples Republic of China. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong. Sino Biopharmaceutica is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US82937X1037 |
| Business Address | Office Tower, Wan |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.sinobiopharm.com |
| Phone | 852 2802 9886 |
| Currency | USD - US Dollar |
Sino Biopharmaceutica Key Financial Ratios
Sino Biopharmaceutica's financial ratios allow both analysts and investors to convert raw data from Sino Biopharmaceutica's financial statements into concise, actionable information that can be used to evaluate the performance of Sino Biopharmaceutica over time and compare it to other companies across industries.| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 | |||
| Beta | 0.51 | |||
| Z Score | 1.2 | |||
| Last Dividend Paid | 0.083 |
Sino Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sino Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Sino Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sino Biopharmaceutica competition to find correlations between indicators driving Sino Biopharmaceutica's intrinsic value. More Info.Sino Biopharmaceutical Ltd is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.16 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sino Biopharmaceutical Ltd is roughly 6.45 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sino Biopharmaceutica by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sino Biopharmaceutica's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Sino Biopharmaceutical Systematic Risk
Sino Biopharmaceutica's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sino Biopharmaceutica volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on Sino Biopharmaceutical correlated with the market. If Beta is less than 0 Sino Biopharmaceutica generally moves in the opposite direction as compared to the market. If Sino Biopharmaceutica Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sino Biopharmaceutical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sino Biopharmaceutica is generally in the same direction as the market. If Beta > 1 Sino Biopharmaceutica moves generally in the same direction as, but more than the movement of the benchmark.
Sino Biopharmaceutica December 3, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Sino Biopharmaceutica help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sino Biopharmaceutical Ltd. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sino Biopharmaceutical Ltd based on widely used predictive technical indicators. In general, we focus on analyzing Sino Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sino Biopharmaceutica's daily price indicators and compare them against related drivers.
| Information Ratio | 0.0412 | |||
| Maximum Drawdown | 25.86 |
Additional Tools for Sino Pink Sheet Analysis
When running Sino Biopharmaceutica's price analysis, check to measure Sino Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sino Biopharmaceutica is operating at the current time. Most of Sino Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sino Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sino Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sino Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.